Jazz Pharmaceuticals agreed to acquire Actio Biosciences and its lead epilepsy drug ABS-1230 in a deal valued at about $1.32 billion. The acquisition expands Jazz’s epilepsy footprint amid persistent unmet need and continued pharma interest in seizure and neurologic disorder pathways. The transaction reflects a broader consolidation pattern in epilepsy, where companies are searching for differentiated clinical-stage candidates that can address efficacy and tolerability gaps. Jazz said the move brings ABS-1230 into its development pipeline earlier in the next phase of product planning. For Actio, the deal is a strategic exit that can accelerate clinical and regulatory work under Jazz’s resources. For Jazz, it offers potential optionality for diversification beyond the company’s current branded neurology portfolio. The timing suggests epilepsy remains a funding-and-M&A magnet where developers compete on mechanism, trial design, and patient subgroups.